BackgroundDevelopment of a core outcome set (COS) for clinical trials for COVID-19 is urgent because of the pandemic wreaking havoc worldwide and the heterogeneity of outcomes in clinical trials. Meth
‘Standardized’ criteria are those as proposed in the reference paper Olliaro et al, 20139; ‘updated’ criteria are those resulting from the consultation.